NeuroScientific Biopharmaceuticals Limited announce the application for an early-phase clinical trial involving lead drug candidate EmtinBTM has been
submitted for Human Research Ethics Committee (HREC) approval, confirming the Company is on schedule to complete the significant milestone of commencing clinical development of EmtinBTM in 1H 2022. The timeline for approval is expected to be consistent with NeuroScientific's plans to commence the clinical trial in June 2022. The early-phase clinical trial is the initial stage of the clinical development program involving EmtinBTM. An
important focus of this study will involve the assessment of biomarkers in human blood samples that indicate proof of the mechanism of activity of EmtinBTM in humans and can be used to guide efficacy outcomes during future trials in patients. The importance of this data is highlighted by the high rate of attrition for drugs in Phase II clinical trials, with up to 70% failing due to lack of efficacy.1 This clinical trial will include up to 30 healthy
participants and will be undertaken by leading WA-based clinical research partner Linear Clinical Research. A complete overview of the clinical development plan to support the neurology treatment indications for EmtinBTM will be provided in a separate announcement in the coming days.